1. "Does CJC-1295 and ipamorelin really work?"
Answer: each raises GH; pair untested. Evidence: human, alone.
Split the question in two. Does each peptide release growth hormone in people? Yes, and the numbers are clean. CJC-1295 with its albumin linker, in two randomized placebo-controlled trials in healthy adults, raised mean GH 2 to 10-fold for 6 days or more and IGF-1 1.5 to 3-fold for 9 to 11 days after one administration [1]; in a second study, a week after one administration, trough GH was 7.5-fold higher, mean GH 46 % higher and IGF-1 45 % higher [2].
Ipamorelin, infused intravenously into healthy men, produced one GH episode at every level, peaking at 0.67 hours [3]. Does the pair, as sold, do anything measurable in people? Nobody knows, because no published study has given the two together; the synergy idea comes from GHRH(1-44) plus GHRP-6 in 18 men in 1990 [5]. Outcomes beyond hormone levels were never measured for these molecules.
2. "DAC or no DAC for the blend?"
Answer: no DAC: time scales match. Evidence: human pk.
No DAC, and the reason is arithmetic. The DAC form binds albumin and lasts 5.8 to 8.1 days [1]; ipamorelin lasts about 2 hours [3]. A pair is supposed to act on the same GH pulse, and a molecule that lingers for a week is acting on all of them. Threads sometimes argue that the DAC form gives "more total GH", which is true as far as the trough data go, but it is a different pharmacology, not a stronger version of the same one. The chemistry and the trade-offs are in CJC-1295 DAC versus no DAC.
3. "How long does each one last?"
Answer: a week with DAC, hours for ipamorelin. Evidence: human pk.
The DAC form of CJC-1295 binds albumin and has a half-life of 5.8 to 8.1 days in healthy adults; after one administration, IGF-1 stayed above baseline for 9 to 11 days [1]. Ipamorelin has a terminal half-life of about 2 hours after an intravenous infusion, and its GH episode peaks at 0.67 hours [3].
The linker-free CJC-1295 found in research blends has no human pharmacokinetic study of its own; its parent sequence, GHRH(1-29), acts for minutes [8]. Pharmacokinetics describe a molecule, not an outcome: none of these figures says anything about an effect in a person.
4. "Does it affect testosterone? Does it raise cortisol?"
Answer: not measured in humans. Evidence: swine only.
Testosterone: nothing published, for either peptide, in humans. The nearest data are from swine, where ipamorelin did not change FSH or LH, the pituitary hormones that govern testosterone [4]. Cortisol: this is the question ipamorelin was designed to answer. Earlier GHRPs raised ACTH and cortisol along with GH; GHRP-6 roughly doubled cortisol and prolactin in men [5]. Ipamorelin, in swine, left ACTH and cortisol at GHRH-reference levels even at more than 200 times its ED50 for GH [4]. That is a strong animal result from the manufacturer; it has never been repeated in a human study, and threads that state "ipamorelin doesn't raise cortisol" as a human fact are extrapolating.
This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release.
5. "Does the response fade with repeated stimulation?"
Answer: slightly, in rats. Evidence: rats only.
One published signal, in rats. After 15 days of repeated ipamorelin, the GH response to a test stimulus was marginally reduced (P < 0.03) while the response to GHRH was unchanged and the pituitary's GH content was normal [6]. So the ghrelin receptor can become slightly less responsive with repeated stimulation, the GHRH receptor in that experiment did not, and the gland was not depleted.
For CJC-1295 the opposite question was studied: does a week of continuous stimulation exhaust the response? One week after a single administration, pulses were intact and the trough was up 7.5-fold [2]. Human data over weeks or months do not exist for either peptide.
6. "What are the downsides of CJC-1295?"
Answer: no serious reactions, small trials. Evidence: human.
From the trials: no serious adverse reactions, and the authors' judgement that the peptide was "safe and relatively well tolerated" [1]. The full text lists the mild to moderate events: injection-site reactions in about 70 % of treated subjects, headache 63 %, diarrhoea 43 % and flushing-type reactions 30 %, the last three mostly in the higher study arms. Flushing is also the known effect of the drug class, in 16 of 18 men after GHRH(1-44) in the 1990 study [5].
What is not known is the consequence of a raised GH trough sustained for months, because the programme that would have found out was terminated in 2006. For ipamorelin the largest safety dataset is 114 surgical patients in whom adverse events were no more frequent than with placebo, 87.5 % against 94.8 % [7]. What was measured for each peptide, and what was not, is listed in the side effects recorded in the trials.
7. "Is it legal, and how do I know the vial is real?"
Answer: not approved; read the COA. Evidence: fda, wada.
Neither peptide is an approved medicine anywhere. They are sold as research chemicals, labelled not for human or veterinary use; the FDA placed ipamorelin acetate in category 2 of its compounding bulk-substances list on September 29, 2023, citing possible immunogenicity [9], and both molecules are named in class S2 of the WADA Prohibited List [10].
As for the vial: a blend certificate has to show two HPLC peaks and two masses, near 3,368 for the linker-free CJC-1295 and 711.9 for ipamorelin, from a named laboratory. Threads that recommend a supplier by name are recommending their own experience; a certificate is a document anyone can read. The checks a buyer can make on a listing are set out under where to get the blend in Europe.
Seven questions, seven answers, and in several of them the honest answer includes "not measured in humans". That is the difference between a thread and the literature, and it is why this site exists.
